Guangxi Wuzhou Zhongheng Group (SHA:600252) received approval from China's National Medical Products Administration to amend some information of its drug, clindamycin phosphate injection, after it passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange filing on Saturday.
Some of the changes included amending the modification to the drug formula and its manufacturing process and revising the drug quality standards.
The drug is mainly used to treat serious infections caused by sensitive anaerobic bacteria, streptococci, pneumococci, staphylococci, and other designated sensitive microorganisms, the Chinese drugmaker said.
The company's shares closed less than 3% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.